The Extraordinary Impact of Big Data on Biomedical Innovation

REGISTER AT MDGBOSTON.ORG
Biomedical development in the 21st century is experiencing an unprecedented information explosion, driving broad and rapid advances.
The convergence of biology with technology and the accompanying big data are creating breakthroughs in all aspects of elucidating, diagnosing, and treating disease. This includes well-known diseases with still unmet needs and many others previously mysterious in origin with no treatments.
In this special MDG Boston Roundtable, we have invited:

• Robert Langer, David H. Koch Institute Professor at MIT
• Janet Woodcock, former Acting Commissioner at the FDA
• Chris Cowles, IP Expert and Partner at Whither & Bergman

This distinguished, highly accomplished panel will delve into particularly exciting aspects of “big data” frontiers now shaping the rapidly emerging landscape of novel platform technologies, IP, regulatory, and much more.

### Agenda (Eastern Time Zone)

• 5:00 – 5:30 PM Eastern Time: Pre-Forum Networking
• 5:30 – 6:30 PM Eastern Time: Forum Roundtable plus Q&A
• 6:30 – 7:00 PM Eastern Time: Post-Forum Networking / Meet the panelists

Venue – Online – TICKETS FREE TO ALL

THE ZOOM LINKS WILL BE PROVIDED DURING REGISTRATION
AND AGAIN VIA EMAIL ON THE DAY OF THE FORUM
Panelists

Robert Langer, PhD
David H. Koch Institute Professor, MIT
Dr. Langer, an extraordinarily prolific biomedical inventor and innovator, is one of 8 Institute Professors at MIT, the highest faculty honor. His 1,500+ articles have been cited over 427,000 times. His 1050+ patents have been licensed or sublicensed to over 400 companies, including Moderna. His over 220 awards include the US National Medal of Science and the US National Medal of Technology and Innovation, and the Charles Stark Draper Prize (often called the Engineering Nobel Prize). He also served as Chairman of the FDA’s Science Board (1999-2002).
Janet Woodcock, MD
Former Acting Commissioner, FDA
Dr. Woodcock has been a trailblazer in modernizing CDER and the FDA, and in shaping FDA policy and legislation at the intersection of science, medicine, and law. In her 38-year tenure at the FDA, she served as FDA Acting Commissioner, Principal Deputy Commissioner, Chief Medical Officer and Director of CDER. During the COVID19 pandemic, she was the therapeutics lead for “Operation Warp Speed”. She received a Lifetime Achievement Award from the Institute for Safe Medication Practices in 2015 and a Biotechnology Heritage Award in 2019.

Chris Cowles, PhD, JD
IP Partner, Whithers & Bergman
Mr. Cowles is a high caliber and top rated intellectual property attorney, being recognized a Massachusetts Rising Star in 2016-2018. He focuses on biotechnology with deep law firm, industry and academic science expertise. His postdoc training was at Whitehead Institute at MIT and prior law firms include Burns & Levinson and Mintz Levin. Clients range from global pharmaceutical companies to start-ups, individual inventors, and academic institutions. He was invited as a panelist at Deloitte’s “Future of Genomics” in 2022.

Forum Organizer & Moderator
Tina Guanting Qiu, MD, PhD
Founder/CEO, Ophthalmic Therapeutic Innovation
Dr. Qiu, a physician-scientist and surgeon-biologist, is a pioneer in leveraging big data for IP and medical innovation. She advises executive leaders in biotech and pharma on solving the most difficult problem for the development of novel medicines: >90% failure rate in attempting to cross the bridge of successful clinical translation. She received an Albert Nelson Marquis Lifetime Achievement Award in 2023 and was recognized as Top Physician Entrepreneur and Innovator of the Year for 2024 by the International Association of Top Professionals (IAOTP).

REGISTER AT MDGBOSTON.ORG